Pharmacodynamic and pharmacokinetic evaluation of CS-526 in cynomolgus monkeys.
In the present study, we evaluated the effect of the novel acid pump antagonist 7-(4-fluorobenzyloxy)-2,3-dimethyl-1-{[(1S,2S)-2-methylcyclopropyl]methyl}-1H-pyrrolo[2,3-d]pyridazine (CS-526) on the intragastric acidity of cynomolgus monkeys. The study was performed in a crossover manner with five male animals. CS-526 was administered orally or intravenously at doses of 3.0, 10 and 30 mg/kg, or 0.3, 1.0 and 3.0 mg/kg, respectively. The time period in which the intragastric pH was 4.0 or more (Time(pH > or = 4.0)) and the median pH were calculated for 24 h after the administration. The intragastric pH was elevated after CS-526 treatment. The Time(pH > or = 4.0) was increased in a dose-dependent manner (p = 0.0292) in the oral administration, and the median pH was also increased in a dose-dependent fashion (p = 0.0491) in the intravenous administration. The plasma concentration of CS-526 and its metabolite R-130185 was increased after oral and intravenous administration of CS-526, except for one animal which did not show any detectable amount of R-130185 after intravenous administration at the lowest dose. The area under the time-concentration curve of the active component was increased in the dose proportional manner after oral and intravenous administration. The absolute bioavailability of the active component was estimated to be approximately 1%. Correlation between the pharmacodynamic parameters and the pharmacokinetic parameters was observed in oral (p = 0.0029-0.0745), but not in intravenous administration (p = 0.0558-0.2789). In conclusion, oral and intravenous administration of CS-526 showed inhibition on gastric acidity in cynomolgus monkeys using intragastric pH-metry and some pharmacokinetic and pharmacodynamic parameters were well correlated.
Ito
Keiichi
K
R&D Operations Department, Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawaku, Tokyo 140-8710, Japan. ito.keiichi.vz@daiichisankyo.co.jp
Kinoshita
Kazuya
K
Yamamura
Naotoshi
N
Tomizawa
Atsuyuki
A
Inaba
Fumi
F
Morikawa-Inomata
Yuka
Y
Tabata
Keiichi
K
Shibakawa
Nobuhiko
N
D000284:Administration, Oral; D000818:Animals; D019540:Area Under Curve; D001682:Biological Availability; D018592:Cross-Over Studies; D004305:Dose-Response Relationship, Drug; D005744:Gastric Acid / Q000378:metabolism*; D005745:Gastric Acidity Determination; D005753:Gastric Mucosa / Q000378:metabolism; D006863:Hydrogen-Ion Concentration; D007275:Injections, Intravenous; D008252:Macaca fascicularis; D008297:Male; D011724:Pyridazines / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology*; D011758:Pyrroles / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology*; D013270:Stomach / Q000187:drug effects*; D013997:Time Factors
C523982:7-(4-fluorobenzyloxy)-2,3-dimethyl-1-((2-methylcyclopropyl)methyl)-1H-pyrrolo(2,3-d)pyridazine; D011724:Pyridazines; D011758:Pyrroles